Genome-wide association studies (GWAS) have identified > 250 loci for body mass index (BMI), implicating pathways related to neuronal biology. Most GWAS loci represent clusters of common, noncoding variants from which pinpointing causal genes remains challenging. Here we combined data from 718,734 individuals to discover rare and low-frequency (minor allele frequency (MAF) < 5%) coding variants associated with BMI. We identified 14 coding variants in 13 genes, of which 8 variants were in genes (ZBTB7B, ACHE, RAPGEF3, RAB21, ZFHX3, ENTPD6, ZFR2 and ZNF169) newly implicated in human obesity, 2 variants were in genes (MC4R and KSR2) previously observed to be mutated in extreme obesity and 2 variants were in GIPR. The effect sizes of rare variants are ~10 times larger than those of common variants, with the largest effect observed in carriers of an MC4R mutation introducing a stop codon (p.Tyr35Ter, MAF = 0.01%), who weighed ~7 kg more than non-carriers. Pathway analyses based on the variants associated with BMI confirm enrichment of neuronal genes and provide new evidence for adipocyte and energy expenditure biology, widening the potential of genetically supported therapeutic targets in obesity.
O besity is a heritable disease and represents a major unmet public-health problem with only a few safe and long-term effective therapies 1 and intervention strategies 2 . In efforts to understand the genetic basis of obesity and identify potential targets for new therapies, GWAS for BMI and obesity risk have identified > 250 common variants over the past decade [3] [4] [5] [6] [7] . Consistent with single-gene disorders of obesity 8 , tissue expression and gene set enrichment analyses for genes implicated in BMI-associated loci have shown that the central nervous system (CNS) has a critical role in body weight regulation 5 . While the numerous GWAS loci have provided insight into broad biological mechanisms underlying body weight regulation, pinpointing the causal gene(s) and variant(s) remains a major challenge 9 , as GWAS-identified variants are typically noncoding and may affect genes at long distance. The association of intronic FTO variants with BMI illustrates the challenges of identifying causal regulatory effects. The proposed causal variant in this locus was found to regulate the expression of nearby RPGRIP1L in some studies [10] [11] [12] , whereas others found that it regulated the distant IRX3 and IRX5 genes in specific cell types 13, 14 .
To expedite mapping of obesity-related genes, we performed an exome-wide search for low-frequency (MAF = 1-5%) and rare (MAF < 1%) single-nucleotide variants (SNVs) associated with BMI using exome-targeted genotyping arrays. A total of 125 studies (N individuals = 718,734) performed single-variant association between up to 246,328 SNVs and BMI. In addition, we performed genebased meta-analyses to aggregate rare and low-frequency coding SNVs across 14,541 genes. Using genetic, functional and computational follow-up analyses, we gained insights into the function of BMI-implicated genes and the biological pathways through which they may influence body weight.
Results
Fourteen rare and low-frequency coding variants in 13 genes. Our study comprises a discovery stage and a follow-up stage (Methods, Supplementary Fig. 1 and Supplementary Tables 1-3 ).
In our primary analysis, the discovery stage included data from 123 studies (N max = 526,508) across five ancestry groups, with individuals predominantly of European ancestry (~85%). Each study performed single-variant association analyses of coding variants present on the exome array, including up to 13,786 common (MAF > 5%) and 215,917 rare or low-frequency coding SNVs (affecting exons and splicing sites). Summary statistics were combined using fixed-effect meta-analyses. SNV associations for rare or lowfrequency variants that reached a suggestive level of significance (P < 2.0 × 10 −6
) were taken forward for follow-up in two European cohorts, deCODE (N max = 72,613) and UK Biobank (N max = 119,613 (interim release)). Overall significance was assessed after combining the results of the discovery and follow-up studies into a final meta-analysis (all-ancestry, sex-combined additive model, N max = 718,734); SNV associations that reached P < 2 × 10 −7 were considered array-wide significant 15, 16 (Table 1, Supplementary Figs. 2-4  and Supplementary Table 4) . In secondary analyses, we performed sex-specific analyses, analyses limited to individuals of European ancestry and analyses using a recessive model of inheritance.
In our primary analysis of rare and low-frequency variants, we identified five rare SNVs in three genes (one in KSR2, two in MC4R and two in GIPR) and nine low-frequency SNVs in eight genes (one in ZBTB7B, two in ACHE, and one each in RAPGEF3, PRKAG1, RAB21, HIP1R, ZFHX3 and ENTPD6) associated with BMI (Table 1 , Box 1, Supplementary Fig. 3a and Supplementary Table 5 ). In secondary analyses, we identified two additional lowfrequency SNVs: one in the all-ancestry, women-only analysis (ZFR2) and one in the European-ancestry-only analysis (ZNF169) ( Table 1 , Supplementary Fig. 3b ,c and Supplementary . Of these 16 SNVs, located in 13 genes, the 2 SNVs in MC4R (r 2 = 1; D′ = 1) and the 2 SNVs in ACHE (r 2 = 0.98; D′ = 0.99) were in high linkage disequilibrium (LD), whereas the two SNVs in GIPR (r 2 = 0; D′ = 0.16) were independent of each other. Hence, the 16 SNVs represent 14 independent variants (4 rare and 10 low frequency), of which 8 are located in genes not previously implicated in BMI Full list of authors and affiliations appear at the end of the paper.
. Effect sizes increased as MAF decreased, in particular for SNVs with MAF < 0.5% (~1 heterozygote carrier in 100 people), consistent with the statistical power of our sample (Fig. 1 ). For example, the nonsense MC4R SNV encoding p.Tyr35Ter (rs13447324, MAF = 0.01%) was present in ~1 in 5,000 individuals and resulted in a ~7-kg increase in body weight for a 1.7-m-tall person. The two GIPR SNVs contributed independently to lower body weight: carriers (1 in ~455 individuals) of p.Arg190Gln (rs139215588) weighed ~1.92 kg (-0.148 s.d. BMI) less than non-carriers and carriers (1 in ~385 individuals) of p.Glu288Gly (rs143430880) weighed ~1.99 kg (-0.153 s.d. BMI) less. Among 115,611 individuals from the UK Biobank, one apparently healthy 61-year-old woman, with no reported illnesses, carried both rare GIPR alleles and weighed ~11.2 kg less (equivalent to -0.86 s.d. BMI or -3.87 kg/m 2 ) than the average non-carrier of the same height ( Supplementary Fig. 8 ). The possible synergistic effect for the two GIPR alleles needs confirmation in additional individuals who carry both variants.
Even though the effect sizes of low-frequency and, in particular, rare SNVs tended to be larger than those of common GWASidentified loci 5 , the 14 SNVs combined explained < 0.1% of BMI variation because of their low population frequencies (Table 1 and  Methods) . Also, although the effects of the four rare SNVs (one each (ZBTB7B, ACHE, RAPGEF3, RAB21, ZFHX3, ENTPD6, ZFR2 and ZNF169) and 6 are located in five loci that were previously identified by GWAS (PRKAG1-BCDIN3D, HIP1R-CLIP1, MC4R and GIPR-QPCTL) 5 and/or through sequencing of severe, early-onset obesity cases (MC4R and KSR2) [17] [18] [19] ( Supplementary Fig. 5 ). Conditional analyses established that the coding SNVs in PRKAG1, MC4R and GIPR were independent of the common lead variants in GWAS loci (rs7138803, rs17782313 and rs2287019, respectively), whereas the SNVs in the HIP1R and GWAS locus near CLIP1 (rs11057405) represent the same signal (Methods, Supplementary Fig. 5 and Supplementary Tables 9 and 10) .
Next, we performed gene-based association tests (sequence kernel association test (SKAT) and variable threshold (VT); broad, strict) in up to 14,541 genes 20 to examine whether these aggregated analyses would yield new evidence of multiple rare or low-frequency coding SNVs in the same gene affecting BMI (Methods). Using broad SNV inclusion criteria, associations for 13 genes reached array-wide significance (P < 2.5 × 10 −6 ) 15, 16 , 4 of which had not been highlighted in single-variant analyses (Table 2 and Supplementary  Table 11 ). Conditional analyses showed that only for GIPR was the gene-based association driven by multiple SNVs (Table 2 and Filled markers indicate that the minor allele is associated with higher BMI, and unfilled markers indicate that the minor allele is associated with lower BMI. Variants were identified in all-ancestry analyses (light blue diamond), European-ancestry-only analyses (dark blue square) and women-only analyses (pink diamond). Effect sizes for previously identified GWAS loci are shown by navy blue diamonds. The dotted line represents 80% power, assuming α = 2 × 10 and N = 525,000 (discovery sample size).
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in KSR2 and MC4R and 2 in GIPR) were large by GWAS standards, penetrance for obesity is still expected to be low. Indeed, using data from the UK Biobank (N max = 119,781), we compared the prevalence of normal weight (18.5 kg/m 2 ≤ BMI < 25 kg/m 2 ) and obesity (BMI ≥ 30 kg/m 2 ) between carriers and non-carriers of these variants (Methods and Supplementary Table 13 ). For the variants in GIPR (p.Arg190Gln and p.Glu288Gly), both of which are BMI-decreasing SNVs, carriers tended (P < 0.05) to have lower obesity prevalence REACTOME GPCR ligand binding Descreased circulating testosterone level  Increased systemic arterial systolic blood pressure  Enhanced lipolysis  Triglyceride catabolic process  Abnomal glucose homeostasis  Increased circulating insulin level  Abnormal lipid homeostasis   ADH1B   ANKS1B  PTPRT  OTUD7A  GRIN2A  GPR37  TENM2  PTPRD  ERC2  MAP1A  ZFR2  KSR2  PDZD7  UHMK1  FRS3  BAIAP3  IGSF1  CARTPT For any given cell, the color indicates how strongly the corresponding gene (x axis) is predicted to belong to the reconstituted gene set (y axis), based on the gene's z score for gene set inclusion in DEPICT's reconstituted gene sets (red indicates a higher z score, and blue indicates a lower z score). To visually reduce redundancy and increase clarity, we chose one representative 'meta-gene set' for each group of highly correlated gene sets based on affinity propagation clustering (Methods and Supplementary Note). Heat map intensity and DEPICT P values (Supplementary Table 17) correspond to the most significantly enriched gene set within the meta-gene set. Annotations for genes indicate (i) whether the gene has an Online Mendelian Inheritance in Man (OMIM) annotation as underlying a monogenic obesity disorder (black/gray), (ii) the MAF of the significant ExomeChip variant (blue), (iii) whether the variant's P value reached array-wide significance (< 2 × 10
) or suggestive significance (< 5 × 10 −4 ) (purple), (iv) whether the variant was new, overlapped 'relaxed' GWAS signals from Locke et al. 5 (GWAS P < 5 × 10
) or overlapped 'stringent' GWAS hits (GWAS P < 5 × 10 −8 ) (pink), and (v) whether the gene was included in the gene set enrichment analysis or excluded by filters (orange/brown) (Methods and Supplementary Note). Annotations for gene sets indicate whether the meta-gene set was significant (green; false discovery rate (FDR)) in the DEPICT analysis of GWAS results
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. Here two regions of particularly strong gene set membership are shown (see full heat map in Supplementary Fig. 10a ).
(21.2% and 20.1%, respectively) than non-carriers (25.1% and 25%). For the MC4R p.Tyr35Ter and KSR2 p.Arg525Gln variants, the prevalence of obesity for carriers (30% and 25.7%, respectively) and non-carriers (25.1% and 25.3%) was not significantly different.
We examined whether rare and low-frequency SNVs affected obesity risk early in life by combining data from three casecontrol studies of childhood obesity (N cases = 4,395; N controls = 13,072) (Methods and Supplementary Table 14) . Associations for 10 of the 13 SNVs were directionally consistent with those observed for BMI in adults (77%, P binomial = 0.046), with 3 of the variants (ZBTB7B, PRKAG1 and RAB21) reaching nominal significance (P < 0.05). Although no carriers of the MC4R mutations were available for analyses, the role of MC4R in body weight regulation in childhood was established almost two decades ago 17, 19, 21 Fig. 9 and Supplementary Table 15) and performed phenome-wide association study (PheWAS) analyses using electronic medical record (EMR) data from BioVu and UK Biobank (Methods and Supplementary Table 16 ). The BMIincreasing allele of the ZBTB7B SNV encoding p.Pro190Ser was associated with greater height, and those for the PRKAG1, ACHE and RAPGEF3 SNVs were associated with shorter height, but association with other traits differed. Specifically, carriers of the serine-encoding allele for PRKAG1 p.Thr38Ser appeared heavier and shorter and had lower HDL cholesterol levels, earlier age at menarche (reported before 23 ) and higher systolic blood pressure, in agreement with PheWAS analyses showing an increased risk of 'malignant essential hypertension' and 'hypertension' (Supplementary Table 16 ). While carriers of the proline-encoding allele for RAPGEF3 p.Leu300Pro were also heavier and shorter, they had a lower BMI-adjusted waist-to-hip ratio (WHR adjBMI ) and lower fasting insulin levels (Supplementary Table 15 ), consistent with PheWAS results showing lower odds of 'secondary diabetes mellitus' (Supplementary Table 16 ). Thus, while all SNVs were associated with BMI, their patterns of association with other traits suggest that they may affect different physiological pathways.
Gene set enrichment analyses. To test whether the BMI-associated rare and low-frequency variants implicate biological pathways, we performed gene set enrichment analyses. Similarly to our previous analysis of GWAS for BMI 5 , we analyzed coding variants that reached P < 5 × 10
, using a DEPICT version adapted for exome array analysis 15 (Methods and Supplementary Note). We used 50 rare and lowfrequency coding variants as input (all P < 5 × 10
; Methods) and observed significant enrichment (Fig. 2, Supplementary Fig. 10a and Supplementary Table 17 ). Many of the enriched gene sets were related to neuronal processes, such as neurotransmitter release and synaptic function (for example, glutamate receptor activity, regulation of neurotransmitter levels and synapse part), consistent with previous findings from GWAS 5 . When we excluded variants near (± 1 Mb with respect to) previously identified GWAS loci, we still observed 29 significantly enriched gene sets (in 12 meta-gene sets) ( Supplementary Fig. 10b and Supplementary Table 18), thereby providing independent confirmation of the GWAS gene set enrichment results. In addition to neuronal-related gene sets, the analyses with rare and low-frequency coding variants newly identified a cluster of metabolic pathways related to insulin action and adipocyte/ lipid metabolism (for example, enhanced lipolysis, abnormal lipid homeostasis and increased circulating insulin level; Fig. 2 ). Finally, we observed that rare and low-frequency BMI-associated coding variants were more effective at identifying enriched gene sets than common coding variants. Specifically, adding 192 common variants. One possible explanation for this is that rare and lowfrequency coding variants may fall in the causal gene more often than common coding variants, which suggests that the rare and low-frequency variants are more likely to be causal rather than simply in LD with causal variants. We also used gene set enrichment analysis to prioritize candidate genes. Among the genes with rare and low-frequency coding . In GTEx, HIP1R is most expressed in stomach tissue, brain (substantia nigra, spinal cord, hippocampus) and sun-exposed skin 74 . KSR2 (kinase suppressor of ras 2). KSR2 is an intracellular protein that functions as a molecular scaffold to regulate the MAP kinases ERK1 and ERK2 and determine cell fate. KSR2 also regulates AMPK activity controlling cellular thermogenesis, fat oxidation and glucose metabolism 18, 60, 61 . Knockout mouse models and human mutations have demonstrated a link with obesity risk 61 . KSR2 is almost exclusively expressed in the brain. It has fewer missense variants than expected and is highly intolerant to loss-of-function mutations 51 .
MC4R (melanocortin 4 receptor). MC4R is a seventransmembrane-domain
G-protein-coupled receptor, predominantly expressed in the brain 74 . MC4R has been known to have a key role in body weight regulation for more than 20 years. Activation of MC4R by α -MSH, a POMC-derived peptide, suppresses food intake; MC4R antagonists increase food intake, and MC4R deficiency in human and rodent models results in hyperphagia and severe and early-onset obesity 79 . More than 150 MC4R mutations have been identified in individuals with severe, early-onset obesity 79 , many of which lead to complete or partial loss of function 50, 80 . Up to 6% of individuals with severe, earlyonset obesity carry pathogenic mutations in MC4R, making MC4R deficiency the most common form of monogenic obesity 50, 80, 81 . PRKAG1 (protein kinase AMP-activated non-catalytic subunit γ1). The protein encoded by PRKAG1 is one of the γ regulatory subunits of AMPK, which is an important energysensing enzyme that monitors cellular energy status 33 . AMPK and PRKAG1 are ubiquitously expressed 74 . In the hypothalamus, AMPK influences food intake, energy expenditure and glucose homeostasis 35 . Muscle-specific overexpression of the AMPK γ 1 subunit in mice results in increased food intake but does not affect body weight, presumably through a compensatory increase in energy expenditure 82 . RAB21 (member RAS oncogene family). RAB21 belongs to the Rab family of monomeric GTPases involved in the control of cellular membrane trafficking. The encoded protein is widely expressed 74 , has a role in the targeted trafficking of integrins and is involved in the regulation of cell adhesion and migration 83 . RAB21 is thought to be intolerant to loss-of-function mutations 51 . RAPGEF3 (rap guanine nucleotide exchange factor 3; also known as EPAC1). RAPGEF3 encodes the exchange protein directly activated by cAMP isoform 1 (EPAC1), one of two cAMP sensors that are involved in numerous intracellular-cAMPmediated functions 84 . EPAC1 is ubiquitously expressed 74 , and insights from mouse knockout models suggest a role in energy homeostasis and the development of obesity and diabetes through the regulation of leptin and insulin signaling 30, 84 .
ZFR2 (zinc-finger RNA-binding protein 2).
The biological function of the gene product is as yet undetermined. Gene Ontology (GO) annotations related to this gene include 'nucleic acid binding' . It may have a role in dendritic branching and axon guidance 85, 86 . ZFR2 is predominantly expressed in the brain 74 . ZBTB7B (zinc-finger-and BTB-domain-containing 7B; also known as ThPOK). ZBTB7B is a transcription factor regulating T cell fate in the thymus, particularly as the master regulator of CD4 
ZNF169 (zinc-finger protein 169).
The biological function of the gene product is as yet unclear. GO annotations suggest that ZNF169 is involved in 'nucleic acid binding' and 'transcriptional regulation' . This gene is ubiquitously expressed 74 . More details and references are given in Supplementary  Table 23. coding SNVs (all P < 5 × 10
) to the analysis decreased the number of enriched gene sets from the 471 (106 meta-gene sets) seen with rare and low-frequency coding SNVs to 62 (24 meta-gene sets) ( Supplementary Fig. 10c and Supplementary Table 19 ). We observed fewer significant gene sets with the combined common and rare/low-frequency analysis, despite including more total coding variants and a higher fraction of array-wide significant coding variants associated with BMI at P < 5 × 10
, a subset of genes were prominently represented in the CNS-related enriched gene sets ( Fig. 2) and are proposed to influence neurotransmission and/or synaptic organization, function and plasticity. These included genes in regions with suggestive evidence of association from GWAS (CARTPT, MAP1A and ERC2) and genes in regions not previously implicated by GWAS (CALY, ACHE, PTPRD and GRIN2A). The non-neuronal metabolic gene sets implicated two genes (CIDEA and ADH1B) that are markers of brown or 'beige' adipose tissue 24, 25 , providing new supporting evidence for a causal role in body weight regulation of this aspect of adipocyte biology.
Drosophila results. To test for potential adiposity-driving effects of gene regulation, we performed tissue-specific RNA interference (RNAi) knockdown experiments in Drosophila melanogaster. We generated adipose-tissue-specific (cg-Gal4) or neuronal-specific (elav-Gal4) RNA interference (RNAi) knockdown crosses for 9 of the 13 candidate genes for which fly orthologs exist (Supplementary  Table 20 ) and performed whole-body triglyceride analysis in male young adult flies. Triglycerides, the major lipid storage form in animals, were chosen as a direct measure of fly adiposity. Both neuronal and fat-body knockdown of zfh2, the ortholog of ZFHX3, resulted in significantly increased triglyceride levels. Adiposetissue-specific, but not neuronal, knockdown of epac (RAPGEF3) was lethal. Tissue-specific loss of function of the other seven genes tested did not affect triglyceride levels.
Rare and low-frequency coding SNVs in genes implicated in monogenic and syndromic obesity. We identified 39 genes in the literature that have been convincingly implicated in monogenic obesity or syndromes for which obesity is one of the main features (Supplementary Fig. 11 and Supplementary Tables 21 and 22 ). Of the 652 rare and low-frequency SNVs in these 39 genes in monogenic and/or syndromic obesity, 5 SNVs were significantly associated with BMI (Bonferroni-corrected P = 7.7 × 10 −5 (= 0.05/652)). Besides the SNVs in MC4R (p.Tyr35Ter and p.Asp37Val) and KSR2 (p.Arg525Gln) already highlighted in the single-variant analyses, we identified an additional SNV in MC4R (p.Ile251Leu) and one in BDNF (p.Glu6Lys) associated with BMI. MC4R p.Ile251Leu has previously been shown to protect against obesity 26 , whereas BDNF p.Glu6Lys, which is independent of SNVs previously identified by GWAS (r 2 = 0.01; D′ = 1.0) 5 , has not been implicated in body weight regulation before. We examined whether the 652 rare and lowfrequency SNVs were enriched for association with BMI as compared to rare and low-frequency coding SNVs in all other genes, but found no evidence to support this.
Discussion
In this meta-analysis of exome-targeted genotyping data, we identified 14 rare and low-frequency coding variants in 13 genes associated with BMI. Eight of these genes (ACHE, ENTPD6, RAB21, RAPGEF3, ZBTB7B, ZFHX3, ZFR2 and ZNF169) have not previously been implicated in human obesity, but evidence from animal studies provides support for a role in energy metabolism for some of these, such as ACHE 27,28 , RAPGEF3 29-32 and PRKAG1 33-38 . Others fall into established BMI GWAS loci (PRKAG1-BCDIN3D, HIP1R-CLIP1, MC4R and GIPR-QPCTL) 5 and/or were previously implicated in severe, early-onset obesity (MC4R and KSR2) [17] [18] [19] and, using this exome-targeted approach, we pinpoint rare and low-frequency variants in these loci that have a role in obesity in Array-wide significant gene-based association is defined as P < 2.5 × 10 −6 . P values are based on the meta-analysis of discovery-stage studies.Gene-based analyses were performed with SKAT and VT; results shown are from the test (SKAT or VT) for which the significance exceeded P < 2.5 × 10 −6 . Only results using the broad SNV inclusion criteria reached array-wide significance. Transcript positions are reported according to Build 37 for the longest coding transcript supported by RefSeq (as displayed in the USCS Genome Browser). a P value after conditioning on the most significant (top) single variant aggregated in the gene-based test.
the general population. Pathway analyses confirm a key role for neuronal processes and newly implicate adipocyte and energy expenditure biology. Consistent with other polygenic traits 15, 23, [39] [40] [41] [42] , we show that large sample sizes are needed to identify associated rare and lowfrequency variants. The observed effect sizes reflect the statistical power of our sample size and are particularly large for SNVs with MAF < 0.05%. The existence of rare alleles with larger effects on BMI than have been observed for common alleles might reflect negative or stabilizing selection on the extremes of BMI. However, rare variants with smaller effects almost certainly exist, but larger samples will be needed to uncover these. Our study was limited to coding variants on the exome array; large-scale sequencing studies will be needed to test for variants not covered by exome arrays.
The strongest association was observed for a mutation in MC4R introducing a stop codon (p.Tyr35Ter, rs13447324, MAF = 0.01%), with carriers weighing on average 7 kg more than non-carriers. MC4R is widely expressed in the CNS and is an established key player in energy balance regulation 43, 44 . Mouse and human studies already showed two decades ago that MC4R deficiency results in extreme obesity, mainly through increased food intake [45] [46] [47] [48] . MC4R p.Tyr35Ter, which results in MC4R deficiency 49 , was one of the first MC4R mutations discovered in individuals with monogenic obesity 17, 19 , in whom the mutation is > 20 times more prevalent than in the general population 17,50-52
. Here we show that MC4R p.Tyr35Ter has a role outside the setting of early-onset and extreme obesity. Despite its large effect, penetrance is low, and this variant does not fit the model of a fully penetrant Mendelian variant. While significantly associated rare and low-frequency coding variants are strong candidates for being causal, the strongest implication of causal genes is provided by association with multiple independent coding variants, as we demonstrate for GIPR. We identified two rare variants in GIPR (p.Arg190Gln, rs139215588, MAF = 0.11%; p.Glu288Gly, rs143430880, MAF = 0.13%) independently associated with lower BMI; carriers of either variant weigh ~2 kg less than non-carriers. Common variants in or near GIPR have been found to associate with lower BMI 53 and delayed glucose and insulin response to an oral glucose challenge 54 . However, the two rare variants influence BMI independently of these common ones and were not associated with type 2 diabetes or the glycemic traits tested. Rodent models have provided strong evidence of a role for GIPR in body weight regulation. Gipr-deficient mice are protected from diet-induced obesity 55 and have an increased resting metabolic rate 56 . Blocking GIP signaling using a vaccination approach in mice on a high-fat diet reduces weight gain, mainly through reduced fat accumulation, mediated by increased energy expenditure 57 . Manipulation of incretins (GIP and GLP1) and their receptors has complex effects on obesity and insulin secretion and action that may differ between humans and mice 58 . The human genetic data suggest that inhibition of GIPR signaling might represent a therapeutic approach for the treatment of obesity 59 . A fourth rare variant, in KSR2 (p.Arg525Gln, rs56214831, MAF = 0.82%), increases body weight by ~740 g/allele. KSR2 is another gene previously implicated in energy metabolism and obesity 18, 60, 61 . In a recent study, mutation carriers were hyperphagic, had a reduced basal metabolic rate and showed severe insulin resistance 18 . Consistent with human data, Ksr2 −/− mice are obese and hyperphagic, and they have reduced energy expenditure 18, [60] [61] [62] . KSR2 is almost exclusively expressed in the brain and interacts with multiple proteins 63 , including AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis 60, 61 . Notably, KSR2 is one of the first genes implicated in severe, early-onset obesity in which mutations affect not only food intake but also basal metabolic rate, and it is thought to act via neuronal effects 18 (Fig. 2) . Despite convincing evidence of association for these four rare variants in MC4R, GIPR and KSR2, the penetrance of these variants for obesity is low (Supplementary Table 13 ). This is consistent with the polygenic and multifactorial nature of obesity, where variants across a range of frequencies and effect sizes contribute to the phenotype in any one person. Despite the low predictive power of the variants, it remains possible that particular variants in any one person may contribute to different balances of underlying physiology and, hence, different responses to treatments. This was illustrated in two patients with monogenic obesity due to POMC mutations; these patients lacked the main activator of MC4R and were effectively treated with an MC4R agonist 64 .
Of the coding variants in the newly identified genes, some have well-known connections with obesity. For example, PRKAG1 encodes the γ 1 subunit of AMPK, a critical cellular energy sensor 33 . In the hypothalamus, AMPK integrates hormonal and nutritional signals with neuronal networks to regulate food intake and wholebody energy metabolism [34] [35] [36] . Furthermore, hypothalamic AMPK is a key regulator of brown adipose tissue in mice 35, 37, 38 . The BMIdecreasing allele at the associated PRKAG1 variant (p.Thr38Ser, rs1126930, MAF = 3.22%) has additional beneficial effects on blood pressure, providing additional genetic support for modulation of AMPK as an ongoing therapeutic avenue for treatment.
ACHE, in which p.His353Asn (rs1799805, MAF = 3.9%) is associated with increased BMI, is another candidate gene related to neuronal biology, involved in the signaling of acetylcholine at neuromuscular junction and brain cholinergic synapses 65, 66 . Inhibitors of ACHE, used to treat moderate-to-severe Alzheimer's disease 67 , result in weight loss in humans, and Ache-deficient mice have delayed weight gain 27, 28 . However, these phenotypes may be indirect consequences of adverse gastrointestinal and neuromuscular effects, respectively 27, 28, 68, 69 . Another low-frequency coding variant (p.Leu300Pro, rs145878042, MAF = 1.1%) is located in RAPGEF3 and has strong effects on multiple other phenotypes. The BMI-increasing allele encoding Pro300 is associated with shorter height, lower WHR adjBMI and lower insulin levels, suggesting that this variant has multiple physiological consequences. Data from animal models also suggest complex effects of RAPGEF3 on adipocyte biology, energy balance and glucose metabolism [29] [30] [31] [32] . For example, in one study, mice with global deletion of Rapgef3 on a high-fat diet were resistant to obesity owing to reduced food intake and had increased glucose tolerance 30 . However, in a similar study, Rapgef3 −/− mice developed severe obesity, increased respiratory exchange ratio and impaired glucose tolerance 32 . Mice with adipose-tissue-specific knockout of Rapgef3 on a high-fat diet are also more prone to obesity and show increased food intake, reduced energy expenditure, impaired glucose tolerance and reduced circulating leptin levels 70 . More research is needed to understand the consequences of RAPGEF3 manipulation.
The remaining genes with significant associations-ENTPD6, HIP1R, RAB21, ZFR2, ZBTB7 and ZFHX3-have no clear prior evidence for a role in energy homeostasis, and in-depth functional follow-up is needed to gain insight into how they affect body weight. Here we performed gene set enrichment analyses to better understand the biology implicated by our genetic data and confirm the importance of neuronal processes, in particular synaptic function and neurotransmitter release, providing an independent validation of previous GWAS findings 5 . The combination of gene set enrichment analyses and association analyses of coding variants also enables us to highlight candidate genes that are both within these gene sets and show association with BMI at rare and low-frequency coding variants. These include genes reaching array-wide significance (for example, ACHE and ZFR2) and others with clear prior evidence for a role in body weight regulation (for example, CARTPT 71 ) but that had not been highlighted in our single-variant or gene-based association analyses. Of note, the enrichment signals were stronger with rare and low-frequency coding variants only than with all coding variants, suggesting that these variants are more likely to be causal and may more often point directly to relevant genes, whereas common coding variants may more often be proxies for common noncoding variants that affect nearby genes.
In addition, our gene set enrichment analyses now provide supporting evidence for a role of non-neuronal mechanisms as well. Specifically, CIDEA and ADH1B are both strongly predicted to be members of enriched gene sets related to insulin action and adipocyte biology, and both are markers that distinguish brown from white fat depots in mice 24 and humans
25
. CIDEA is predominantly expressed in adipose tissue and is known as a key regulator of energy metabolism 24 . Cidea-deficient mice are resistant to dietinduced obesity with increased lipolysis and mitochondrial uncoupling 24 . The connection of ADH1B with obesity is less clear, but the gene is highly expressed in human adipocytes, has been implicated by gene expression analyses in obesity and insulin resistance, and functions early in a potentially relevant metabolic pathway (retinoid biosynthesis) 24, 25, 72, 73 . Similar pathways were implicated by recent work dissecting the signal near FTO 13 . However, because SNV association signals at ADH1B and CIDEA did not reach array-wide significance, additional genetic analysis of the role of these genes in obesity would be warranted.
In summary, we performed association analyses of rare and lowfrequency variants with BMI in > 700,000 individuals and identified 14 associated variants in 13 genes, including 5 known and 8 new genes. Although each variant contributes little to BMI variation in the general population, the variants may have substantial impact on body weight at an individual level. Furthermore, prior literature for these genes and unbiased gene set enrichment analysis indicate a strong role for neurobiology in body weight regulation and also provide new support for a causal role for aspects of adipocyte biology. The identified genes provide potential targets that may lead to new and more precise approaches for the treatment of obesity, where there has been minimal innovation over the past 30 years 1 .
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-017-0011-x. height. Nature 542, 186-190 (2017 Table 23) , we observed a marked genomic inflation of the test statistics even after adequate control for population stratification (linear mixed model) arising from common markers (λ GC = 1.99; Supplementary Fig. 2a and Supplementary Table 25 ). Such inflation is expected for a highly polygenic trait like BMI, as was previously confirmed for height 15 , and is consistent with our very large sample size 5, 104 . Furthermore, some of the inflation may be due to the design of the ExomeChip, which besides rare and lowfrequency coding SNVs also contains (common and noncoding) SNVs that include previously identified GWAS loci for all traits, including for BMI and BMI-related traits, reported in the GWAS catalog at the time of its design.
After removing established loci (± 1 Mb), the excess of significant associations was markedly reduced and inflation was reduced ( Supplementary Fig. 2c,d) .
Furthermore, to exclude the possibility that some of the observed associations between BMI and rare/low-frequency SNVs could be due to allele calling problems in the smaller studies, we performed a sensitivity meta-analysis with primarily European-ancestry studies totaling > 5,000 participants. We found very concordant effect sizes, suggesting that smaller studies do not bias our results (Supplementary Fig. 12 ).
Follow-up analysis. We sought additional evidence for association of the top signals (P < 2.0 × 10
) identified in the discovery meta-analysis using two independent studies from the UK (UK Biobank, interim release, N = 119,613) and Iceland (deCODE, N = 72,613) (Supplementary Tables 1-3) . We used the same quality control and analytical methodology as described above. We used inverse-varianceweighted fixed-effects meta-analysis in METAL 105 to combine the discovery and follow-up association results. Significant associations were defined at P < 2 × 10
in the combined meta-analysis of discovery, UK Biobank and deCODE results.
Effect of study design. To investigate the potential effect of study design of the participating studies, we tested for heterogeneity between population-based, all case-control studies; T2D case-control studies (Supplementary Table 26 ). None of these comparisons showed significant evidence of heterogeneity (P < 7.4 × 10 Conditional analyses. The RareMETALS R package 103 was used to identify independent BMI-associated signals across the all-ancestry meta-analysis results in the discovery phase. RareMETALS performs conditional analyses by using covariance matrices from each individual cohort to distinguish true signals from the shadows of adjacent significant variants in LD. The conditional associations of all the variants within 1 Mb of each rare or low-frequency coding variant were analyzed (i) to identify nearby secondary signals and (ii) to determine independence from nearby noncoding variants or previously identified GWAS loci (previously defined as a window of 1 Mb surrounding the lead SNP). Gene-based conditional analyses were also performed in RareMETALS.
Owing to the selective coverage of variants on the ExomeChip, we also conducted the respective conditional analyses in the UK Biobank dataset that included 847,441 genome-wide genotyped markers and 72,355,667 variants imputed against the UK10K haplotype reference panel, merged with the 1000 Genomes Phase 3 reference panel. Where available, directly genotyped variants were used for conditional analyses. Otherwise, imputed variants with good imputation quality (IMPUTE2 info score > 0.6) were used. We used QCTOOL to extract variants of interest from the original imputed dataset. Subsequently, GTOOL was used to convert to PLINK format (genotype calling threshold 0.99), and results were merged with the directly genotyped variants for conditional analyses in PLINK v1.90b3.35 64 bit (25 March 2016).
Conversion of effect size and explained variance. We assumed that 1 s.d. = 4.5 kg/ m 2 BMI units, on the basis of population-based data, and used 1.7 m as the average height of a person to convert effect sizes in s.d. units into body weight. The variance explained by each variant was calculated using the effect allele frequency (f) and beta (β) from the meta-analyses with the formula 106 of explained variance
Penetrance analysis. We examined the penetrance for the four rare SNVs-p. Arg525Gln (rs56214831) in KSR2, p.Tyr35Ter (rs13447324) in MC4R, and p.Arg190Gln (rs139215588) and p.Glu288Gly (rs143430880) in GIPR-in European-ancestry data from the UK Biobank (N up to 120,000). For each variant, we compared the prevalence of underweight (BMI < 18.5 kg/m test to test for differences between distributions and a χ 2 for linear trend to test whether distributions of carriers were shifted in comparison to non-carriers. For p.Arg525Gln in KSR2 and p.Tyr35Ter in MC4R, we hypothesized that obesity prevalence was higher in carriers than in non-carriers, whereas for the two GIPR variants we hypothesized that the prevalence of normal weight was higher in carriers than non-carriers.
M et ho ds
Study design and participants. The discovery cohort consisted of 123 studies (163 datasets) comprising 526,508 adult (≥ 18 years) individuals of the following ancestries ( Supplementary Fig. 1 ): (i) European (N = 449,889), (ii) South Asian (N = 29,398), (iii) African (N = 27,610), (iv) East Asian (N = 8,839) and (v) Hispanic (N = 10,772). All participating institutions and coordinating centers approved this project, and informed consent was obtained from all study participants. Discovery meta-analyses were carried out in each ancestry group separately and in an all-ancestry combined group, for both sex-specific and sex-combined analyses. SNVs for which associations reached suggestive significance (P < 2.0 × 10
) in the discovery analyses were taken forward for follow-up in 192,226 individuals of European ancestry from the UK Biobank and deCODE. Conditional analyses were conducted in the all-ancestry and European-descent groups. Study-specific design, sample quality control and descriptive statistics are provided in Supplementary  Tables 1-3 .
Phenotype. BMI (weight (in kg)/height (in m)
2 ) was corrected for age, age 2 and genomic principal components (derived from GWAS data, the variants with MAF > 1% on ExomeChip or ancestry-informative markers available on the ExomeChip), as well as any additional study-specific covariates (for example, recruiting center) in a linear regression model. For studies with non-related individuals, residuals were calculated separately by sex, whereas for family-based studies sex was included as a covariate in the model. Additionally, residuals for case-control studies were calculated separately. Finally, residuals were subjected to inverse normal transformation 93 .
Genotype calling. The majority of studies followed a standardized protocol and performed genotype calling using the designated manufacturer's software, which was then followed by zCall 94 . For ten studies, participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the raw intensity data for the samples from seven genotyping centers were assembled into a single project for joint calling 95 . Study-specific quality control measures of the genotyped variants were implemented before association analysis (Supplementary Table 3 ).
Statistical analyses.
Study-level association analyses. Individual cohorts were analyzed separately for each ancestry group, in sex-combined and sexspecific groups, with either RAREMETALWORKER (see URLs) or RVTEST 96 (Supplementary Table 2 ), to associate inverse-normal-transformed BMI with genotype, accounting for potential cryptic relatedness (kinship matrix), in a linear mixed model. These software tools are designed to perform score-statistics-based rare variant association analyses, can accommodate both unrelated and related individuals, and provide single-variant results and variance-covariance matrices. The covariance matrix captures LD relationships between markers within 1 Mb, which is used for gene-level meta-analyses and conditional analyses 97 . Singlevariant analyses were performed for both additive and recessive models.
Centralized quality control. A centralized quality control procedure, implemented in EasyQC 98 , was applied to individual cohort association summary statistics to identify cohort-specific problems: (i) assessment of possible problems in BMI transformation, (ii) comparison of allele frequency alignment against 1000 Genomes Project phase 1 reference data to pinpoint any potential strand issues and (iii) examination of quantile-quantile plots per study to identify any problems arising from population stratification, cryptic relatedness and genotype biases.
Meta-analyses. Meta-analyses were carried out by two different analysts at two sites in parallel. We excluded variants with a call rate < 95%, Hardy-Weinberg equilibrium P value < 1 × 10 −7 or large allele frequency deviations from reference populations (> 0.6 for all-ancestry analyses and > 0.3 for ancestry-specific population analyses). Significance for single-variant analyses was defined at the array-wide level (a Bonferroni-corrected threshold of P < 2 × 10 −7 for ~250,000 SNVs). To test for sex differences of the significant variants (P < 2 × 10 −7 ), we calculated the P-diff for each SNP, which tests for differences between womenspecific and men-specific β estimates using EasyStrata 99 . For gene-based analyses, we applied the SKAT 100 and VT 101 gene-based methods using two different sets of criteria (broad and strict) to select predicted damaging rare and low-frequency variants with MAF < 5%, based on coding variant annotation from five prediction algorithms (PolyPhen-2 HumDiv and HumVar, LRT, MutationTaster and SIFT) 20 . Our 'broad' gene-based tests included nonsense, stop-loss, splice-site and missense variants that were annotated as damaging by at least one algorithm mentioned above. Our 'strict' gene-based tests included only nonsense, stop-loss, splice-site and missense variants annotated as damaging by all five algorithms. Statistical significance for gene-based tests was set at a Bonferroni-corrected threshold of P < 2.5 × 10 −6 for about 20,000 genes 16, 102 . Singe-variant and genebased meta-analyses were both performed using the RareMETALS R package 103 . As our secondary analyses were nested and/or highly correlated with our primary analysis, we chose the same, already stringent Bonferroni-corrected significance threshold for both analyses. and with minor allele count of 5 or greater in cases and controls were eligible for analysis. Series of logistic regression analyses were then performed in individuals of European ancestry for each eligible genotype-phenotype combination while adjusting for five genetic ancestry principal components. Odds ratios from genotype-phenotype combinations present in both BioVU and the UK Biobank were then aggregated using inverse-variance-weighted fixed-effects meta-analysis. Associations with P values corresponding to a FDR cutoff of less than 10% were considered statistically significant.
Gene set enrichment analysis. We adapted DEPICT, a gene set enrichment analysis method for GWAS data, for use with the ExomeChip (EC-DEPICT). DEPICT's primary innovation is the use of 'reconstituted' gene sets, where many different types of gene sets (e.g., canonical pathways, protein-protein interaction networks and mouse phenotypes) were extended through the use of large-scale microarray data (see ref. 108 for details). EC-DEPICT computes P values on the basis of Swedish ExomeChip data (Malmö Diet and Cancer (MDC), All New Diabetics in Scania (ANDIS) and Scania Diabetes Registry (SDR) cohorts, N = 11,899) and, unlike DEPICT, takes as input only coding variants and only the genes directly containing these variants, rather than all genes within a specified amount of LD (Supplementary Note).
Four analyses were performed for the BMI EC variants: (i) all coding variants with P < 5 × 10
, (ii) all coding variants with P < 5 × 10 −4 independent of known GWAS variants 5 , (iii) all coding rare and low-frequency variants with P < 5 × 10
and (iv) all coding rare and low-frequency variants with P < 5 × 10 −4 independent of known GWAS variants. Affinity propagation clustering 3 was used to group highly correlated gene sets into meta-gene sets. For each meta-gene set, the member gene set with the best P value was used as representative for the purposes of visualization (Supplementary Note). DEPICT for ExomeChip was written using the Python programming language (see URLs for the link to the code on GitHub).
Drosophila RNAi knockdown experiments. For each of the 13 genes in which rare and low-frequency coding variants were associated with BMI, we searched for the corresponding orthologs in Drosophila in the Ensembl ortholog database. Orthologs were available for nine genes but missing for ZBTB7B, MC4R, GIPR and ZNF169. For each of the nine genes, we generated crosses with RNAi knockdown specifically in adipose tissue (cg-Gal4) and neurons (elav-Gal4), leveraging upstream activation sequence (UAS)-inducible short hairpin knockdown lines, available through the Vienna Drosophila Resource Center (VDRC). We crossed male UAS-RNAi flies and elav-GAL4 or CG-GAL4 virgin female flies. All fly experiments were carried out at 25 °C. Five-to 7-d-old males were sorted into groups of 20, weighed and homogenized in PBS with 0.05% Tween with Lysing Matrix D in a beadshaker. The homogenate was heat inactivated for 10 min in a thermocycler at 70 °C. 10 µ l of the homogenate was subsequently used in a triglyceride assay (Sigma, Serum Triglyceride Determination Kit) that was carried out in duplicate according to the protocol with one alteration: samples were cleared of residual particulate debris by centrifugation before absorbance reading. Resulting triglyceride values were normalized to fly weight and larval/population density. We used the non-parametric Kruskal-Wallis test to compare wild-type with knockdown lines.
Enrichment analysis genes associated with monogenic obesity. We identified 39 genes with strong evidence that disruption causes monogenic or syndromic forms of obesity (Supplementary Table 21 ). To test whether these genes are enriched for rare or low-frequency coding variant associations with BMI, we conducted simulations by matching each of the 39 genes with other genes on the basis of gene length and number of variants tested, to create a matched set of genes. We generated 1,000 matched gene sets from our data and assessed how often the number of rare and low-frequency coding variants that exceeded the given significance thresholds was greater in our monogenic/syndromic obesity gene set than in the matched gene sets. 105 . In the CHOP study, cases (1,358 boys, 1,060 girls) were defined as having a BMI greater than the 95th percentile at any point in their childhood. Controls (1,412 boys, 1,143 girls) were defined as having BMI below the 50th percentile consistently throughout childhood. The BMI percentiles are based on the CDC 2000 Growth Charts. All children were classified on the basis of their BMI measurements between the ages of 2 and 18. All individuals were of European ancestry and were collected at the Children's Hospital of Philadelphia. Informed consent was obtained from all study participants, and study protocols were approved by the local ethics committees. Genotypes were obtained using the HumanHap550v1, HumanHap550v3 and Human610-Quad high-density SNP arrays from Illumina. The intersection of all SNPs on the arrays was used in all subsequent preimputation analyses. Before imputation, we excluded SNPs with a Hardy-Weinberg equilibrium P value < 1.0 × 10 −6
, call rate of < 95% or MAF of < 1%. The genotypes were then prephased using SHAPEIT2 and imputed using the 1000 Genomes phase 1 integrated variant set with IMPUTE2. After imputation, SNPs were excluded if the INFO score was < 0.4. Boys and girls were analyzed separately using a logistic regression of case and control status, adjusting for three eigenvectors, and summary statistics were combined using a fixed-effects inversevariance meta-analysis with METAL 105 . SCOOP is a subcohort of the Genetics of Obesity Study (GOOS) cohort. It includes > 1,500 UK European-ancestry individuals with severe, early-onset obesity (BMI s.d. score > 3 and obesity onset before the age of 10 years), in whom known monogenic causes of obesity have been excluded (cases with MC4R mutations were excluded). Two case-control analyses with SCOOP cases were performed: (i) SCOOP versus UKHLS, for which array (Illumina HumanCoreExome) data were available, and (ii) SCOOP versus INTERVAL, for which whole-exome sequencing data were available.
For the array-based analyses, UKHLS controls were genotyped on the Illumina HumanCoreExome-12v1-0 BeadChip. SCOOP cases and 48 UKHLS controls were genotyped on the Illumina HumanCoreExome-12v1-1 BeadChip. The 48 overlapping UKHLS samples were used for quality control to ensure that there were no systematic differences and bias between the two versions of the chip. SCOOP and UKHLS samples were phased with SHAPEITv2, and imputed with IMPUTE2 using the combined UK10K-1000 Genomes phase 3 reference panel. For the whole-exome sequencing analyses, SCOOP versus INTERVAL controls were whole-exome sequenced within the UK10K-EXOME project (Agilent v3) and the INTERVAL project (Agilent v5), respectively, and were then jointly called and subjected to quality control on the union of the sequencing baits. Individuals overlapping or related between the array-based and whole-exome sequencing studies were removed.
After quality control, 1,456 SCOOP and 6,460 UKHLS (BMI range 19-30) individuals and 521 SCOOP and 4,057 INTERVAL individuals were available for the two analyses; all were unrelated, of high quality and of European ancestry. For both analyses (i.e., SCOOP versus UKHLS and SCOOP versus INTERVAL), a maximum-likelihood frequentist association test with the additive genetic model was implemented in SNPTEST v2.5. In the SCOOP versus UKHLS analysis, sex and the first six principal components were included as covariates and variants with a SNPTEST INFO score < 0.4 and Hardy-Weinberg equilibrium P value < 1 × 10 −6 were removed. For the SCOOP versus INTERVAL analysis, we performed an unadjusted analysis (adjustment for principal components did not sufficiently change the results) and variants were limited to those covered at ≥ 7× in at least 80% of each sequencing cohort, meeting the VQSR threshold of -2.52, missingness < 80%, Hardy-Weinberg equilibrium P value < 1 × 10 −8 and GQ ≥ 30.
Cross-trait analyses. We evaluated each of the 14 rare and low-frequency SNVs for association with other relevant obesity-related traits and conditions. We performed lookups in ExomeChip meta-analysis results from other consortia, including our own, GIANT Consortium (height 15 , WHR adjusted for BMI 24 ), MAGIC (HbA1c, fasting insulin, fasting glucose, 2-h glucose), GLGC (HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), triglycerides and total cholesterol), IBPC 39 (systolic and diastolic blood pressure), REPROGEN 23 (age at menarche and menopause) and GoT2D/T2D-GENES 16 (type 2 diabetes). Associations were considered significant at P < 2.0 × 10 −5 , accounting for multiple testing.
Phenome-wide association analysis. To evaluate the potential for pleiotropic effects for SNPs discovered from primary analyses, we performed PheWAS using genotype and phenotype data from two independent sources of EHRs: the Vanderbilt University Medical Center Biorepository (BioVU) and the UK Biobank. The phenotype selection and analysis strategies were synchronized across sites. A total of 1,502 hierarchical phenotype codes from EHRs were curated by grouping International Classification of Disease, Ninth Revision (ICD-9) clinical/ billing codes as previously described 107 . Phenotype codes with 20 or more cases nature research | life sciences reporting summary
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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Describe the software used to analyze the data in this study.
The software used has been described in the Online Methods section, from Page 51 to Page 59. URLs and reference are provided when available. Softwares are: zCall, RAREMETALWORKER, RVTEST, EasyQC, EasyStrata, RareMETALS , METAL, IMPUTE2, QCTOOL, PLINK, SHAPEITv2, EC-DEPICT In addition, study-specific software, used by each study to perform analyses is listed in Supplementary Table 2 .
For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.
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